Stifel Nicolaus restated their buy rating on shares of Shire PLC (NASDAQ:SHPG) in a research note published on Sunday, October 8th. The firm currently has a $245.00 target price on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on SHPG. Cantor Fitzgerald set a $222.00 price objective on Shire PLC and gave the company a buy rating in a research report on Saturday, July 1st. Jefferies Group LLC reissued a hold rating and set a $206.00 price objective (down previously from $216.00) on shares of Shire PLC in a research report on Wednesday, August 9th. Barclays PLC lowered Shire PLC from an overweight rating to an equal weight rating in a research report on Friday, August 11th. Sanford C. Bernstein reissued a market perform rating and set a $210.00 price objective on shares of Shire PLC in a research report on Thursday, July 13th. Finally, Royal Bank Of Canada reissued a buy rating and set a $213.00 price objective on shares of Shire PLC in a research report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock has an average rating of Hold and an average target price of $219.25.
Shire PLC (NASDAQ:SHPG) opened at 145.25 on Friday. The firm has a market cap of $43.26 billion, a P/E ratio of 64.99 and a beta of 1.63. Shire PLC has a 12-month low of $139.36 and a 12-month high of $192.64. The firm’s 50-day moving average is $153.97 and its 200 day moving average is $164.18.
Shire PLC (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. Equities analysts forecast that Shire PLC will post $14.92 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Stifel Nicolaus Reiterates “Buy” Rating for Shire PLC (NASDAQ:SHPG)” was first published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/shire-plcs-shpg-buy-rating-reiterated-at-stifel-nicolaus/1703615.html.
The business also recently disclosed a semiannual dividend, which was paid on Friday, October 20th. Investors of record on Friday, September 8th were paid a dividend of $0.1527 per share. The ex-dividend date of this dividend was Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 41.07%.
Several large investors have recently made changes to their positions in SHPG. Hartford Financial Management Inc. grew its stake in shares of Shire PLC by 5.4% during the 2nd quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 32 shares during the period. YorkBridge Wealth Partners LLC grew its stake in shares of Shire PLC by 81.7% during the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 317 shares during the period. Pacer Advisors Inc. bought a new position in shares of Shire PLC during the 2nd quarter valued at approximately $171,000. Stephens Inc. AR bought a new position in shares of Shire PLC during the 1st quarter valued at approximately $179,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of Shire PLC by 45.3% during the 1st quarter. Tower Research Capital LLC TRC now owns 1,122 shares of the biopharmaceutical company’s stock valued at $195,000 after acquiring an additional 350 shares during the period. Institutional investors own 19.24% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.